Theramed Announces Closing of $350,000 of Senior Convertible Notes to Fund Extraction Operations

VANCOUVER, BC / ACCESSWIRE / August 12, 2019 / Theramed Health Corporation (CSE:TMED)(OTCQB:EVAHF) (the “Company”) is pleased to announce it has closed on a senior convertible debenture financing of $350,000 for working capital, and to fund operations of its extraction facility.

The convertible debenture notes will be 10.00% senior secured notes due five years from the date of issuance, issued in Unit denominations of $1,000. Up to 350 Units or $350,000 will be issued and each Unit shall have 20,000 common share purchase warrants of the company attached to it to be convertible at a price of $0.05 per common share. In addition, each holder of Units will receive a right to certain cash royalties pursuant to a Royalty Agreement, of 5% of gross revenues from the extraction operations. The convertible debenture notes shall also be secured against assets of the operations.

A finder’s fee of 8.00% of the gross proceeds raised pursuant to the offering is payable in Common Shares with a deemed value of $0.05, and 8.00% of the number of Units issued pursuant to the offering payable in finder’s warrants bearing the same terms as the Warrants. In addition, the finder will receive 8% of the cash royalties paid pursuant to the Royalty Agreement.


Website /
CSE Micro-site:
US OTC Markets (OTCQB):



Theramed Health Corporation – is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company has recently been focused on utilizing CBD derived from Hemp as a core component. The company through its subsidiaries has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “CBD Health System” for monitoring, dosing, and recording the effects of CBD on your cardiovascular system.


This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on,, and This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

SOURCE: Theramed Health Corporation

View source version on

error: Content is protected !!